^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Campath (alemtuzumab) (CD52 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma...Suggested treatment regimens…CLL/SLL with del(17p)/TP53 mutation…First-Line Therapy…Other recommended regimens...Alemtuzumab +/- rituximab
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)

    Excerpt:
    Alemtuzumab is recommended in elderly patients with CLL and del(17p) or TP53 mutation.
    DOI:
    10.1093/annonc/mds517
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Blood
    Title:

    Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

    Excerpt:
    …15 (42%) of the patients had p53 mutations or del(17)(p13.1). These patients included 8 with both a point mutation and deletion 17(p13.1), 4 del(17)(p13.1), and 3 p53 point mutations….The median response duration for this subset of patients was 8 months (range, 3-17 months). These data suggest that alemtuzumab may be an effective therapy for patients with CLL with p53 mutations or deletions.
    DOI:
    https://doi.org/10.1182/blood-2003-10-3729